3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
51
Rectal Neoplasms
27
Colonic Neoplasms
16
Stomach Neoplasms
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
9
Adenocarcinoma Of Esophagus
7
Esophageal Neoplasms
6
Neoplasms
5
Cholangiocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Adenocarcinoma
3
Ovarian Neoplasms
2
Liver Neoplasms
2
Intestinal Neoplasms
2
Gastrointestinal Neoplasms
2
Gastrointestinal Diseases
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Biliary Tract Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Adenocarcinoma
1
Operable T2-3N+M0 Rectal Cancer (Stage III)
1
Neurotoxicity Syndromes
1
Metastatic Colorectal Adenocarcinoma
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Locally Advanced Colorectal Carcinoma
1
Intestinal Diseases
1
Interventions
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Paclitaxel
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Bortezomib
2
vandetanib
1
umbralisib
1
ublituximab
1
regorafenib
1
pomalidomide
1
pembrolizumab
1
nilotinib
1
marizomib
1
lutetium Lu 177 dotatate
1
grapiprant
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
cemiplimab
1
carotuximab
1
axicabtagene ciloleucel
1
avelumab
1
Thioctic Acid
1
Tamoxifen
1
Receptors, Interleukin-6
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease Progression
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts